<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755560</url>
  </required_header>
  <id_info>
    <org_study_id>TOXOCARA-ALBENDAZOLE</org_study_id>
    <nct_id>NCT00755560</nct_id>
  </id_info>
  <brief_title>Treatment of Asymptomatic Toxocariasis With Albendazole in Children</brief_title>
  <official_title>Treatment of Asymptomatic Toxocariasis With Albendazole in Children. A Prospective, Randomized, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Niños R. Gutierrez de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Niños R. Gutierrez de Buenos Aires</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate effectiveness of albendazole in the treatment of the
      asymptomatic infection with the parasite Toxocara in children. Treatment response is defined
      as a reduction in the number of eosinophils in blood. The study drug will be compared to
      placebo and randomly assigned in a double blind manner. Follow up will be prospective. 50
      children (25 per group) will be enrolled in the study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean absolute reduction in eosinophil count from baseline</measure>
    <time_frame>12 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in eosinophil count in more than 60% from baseline</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse drug events</measure>
    <time_frame>3, 6, 9 and 12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute reduction in eosinophil count</measure>
    <time_frame>3, 6, 9 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Toxocariasis</condition>
  <arm_group>
    <arm_group_label>Albendazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albendazole 10 - 15 mg/kg/day BID for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Albendazole 10 - 15 mg/kg/day BID for 15 days</description>
    <arm_group_label>Albendazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID for 15 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric ambulatory patients with asymptomatic toxocariasis

          -  Children 2 - 15 years old

          -  Absolute eosinophil count &gt; 1100 / mm3

          -  Normal ophthalmoscopy

        Exclusion Criteria:

          -  Treatment with a benzimidazole in the previous year

          -  Infection by other nematodes (Ascaris lumbricoides, strongyloides stercoralis,
             uncinarias, Trichuris trichuria)

          -  Symptomatic patients (prolonged fever, acute pneumonitis, hepatomegaly, splenomegaly,
             ocular compromise due to toxocara)

          -  Concomitant diseases

          -  Immunocompromised patients

          -  Altered liver or kidney function

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Altcheh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Parasitology Division, Children's Hospital &quot;R Gutierrez&quot; of Buenos Aires</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hector Freilij, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parasitology Division, Children's Hospital &quot;R Gutierrez&quot; of Buenos Aires</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parasitology Division, Children's Hospital &quot;R Gutierrez&quot; of Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2008</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Niños R. Gutierrez de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Dr Jaime Altcheh</investigator_full_name>
    <investigator_title>Service Head, Parasitology and Chagas Service</investigator_title>
  </responsible_party>
  <keyword>Toxocara</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Albendazole</keyword>
  <keyword>eosinophilia</keyword>
  <keyword>parasitology</keyword>
  <keyword>pediatric clinical pharmacology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toxocariasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

